FCCC LOGO Faculty Publications
Al-Katib A , Arnold AA , Aboukameel A , Sosin A , Smith P , Mohamed AN , Beck FW , Mohammad RM
I-kappa-kinase-2 (IKK-2) inhibition potentiates vincristine cytotoxicity in non-Hodgkin's lymphoma - art. no. 228
Molecular Cancer. 2010 Sep;9 :228-228
PMCID: PMC2940845   
Back to previous list
Abstract
Background: IKK-2 is an important regulator of the nuclear factor-kappa B (NF-kappa B) which has been implicated in survival, proliferation and apoptosis resistance of lymphoma cells. In this study, we investigated whether inhibition of IKK-2 impacts cell growth or cytotoxicity of selected conventional chemotherapeutic agents in non-Hodgkin's lymphoma. Two established model systems were used; Follicular (WSU-FSCCL) and Diffuse Large Cell (WSU-DLCL2) Lymphoma, both of which constitutively express p-I kappa B. A novel, selective small molecule inhibitor of IKK-2, ML120B (N-[6chloro-7-methoxy-9H beta carbolin-8-yl]-2-methylnicotinamide) was used to perturb NF-kappa B in lymphoma cells. The growth inhibitory effect of ML120B (M) alone and in combination with cyclophosphamide monohydrate (C), doxorubicin (H) or vincristine (V) was evaluated in vitro using short-term culture assay. We also determined efficacy of the combination in vivo using the SCID mouse xenografts. Results: ML120B down-regulated p-I kappa B alpha protein expression in a concentration dependent manner, caused growth inhibition, increased G0/G1 cells, but did not induce apoptosis. There was no significant enhancement of cell kill in the M/C or M/H combination. However, there was strong synergy in the M/V combination where the vincristine concentration can be lowered by a hundred fold in the combination for comparable G2/M arrest and apoptosis. ML120B prevented vincristine-induced nuclear translocation of p65 subunit of NF-kappa B. In vivo, ML120B was effective by itself and enhanced CHOP anti-tumor activity significantly (P = 0.001) in the WSU-DLCL2-SCID model but did not prevent CNS lymphoma in the WSU-FSCCL-SCID model. Conclusions: For the first time, this study demonstrates that perturbation of IKK-2 by ML120B leads to synergistic enhancement of vincristine cytotoxicity in lymphoma. These results suggest that disruption of the NF-kappa B pathway is a useful adjunct to cytotoxic chemotherapy in lymphoma.
Notes
Al-Katib, Ayad Arnold, Alan A. Aboukameel, Amro Sosin, Angela Smith, Peter Mohamed, Anwar N. Beck, Frances W. Mohammad, Ramzi M. Biomed central ltd London 658aw